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 Abstract 
Microsponge is recent novel technique for control release and target specific drug delivery system. Therefore 
many scientist or researcher attracted towards the microsponge drug delivery system. Also Microsponge technology has 
been introduced in topical drug products to facilitate the controlled release of active drug into the skin in order to reduce 
systemic exposure and minimize local cutaneous reactions to active drugs. More and more developments in delivery 
systems are being integrated to optimize the efficacy and cost-effectiveness of the therapy. Microsponge technology offers 
entrapment of ingredients and is believed to contribute towards reduced side effects, improved stability, increased elegance, 
and enhanced formulation flexibility. In addition, numerous studies have confirmed that microsponge systems are non-
irritating, non-mutagenic, on-allergenic, and non-toxic. Microsponge drug delivery system technology is being used 
currently in cosmetics, over-the-counter (OTC) skin care, sunscreens and prescription products.  
Keywords: Solubility Enhancement, Dissolution Rate, Novel Drug Delivery System, Immediate Release Drug Delivery. 
1. Introduction  
Microsponges are polymeric drug delivery systems 
composed of porous microspheres. They are tiny sponge-
like spherical particles with a large porous surface [1]. 
Moreover, they may enhance stability, reduce side effects 
and modify drug release favourably. Microsponge 
technology has many favourable characteristics, which 
make it a versatile drug delivery vehicle [2]. Microsponge 
Systems are based on microscopic, polymer-based 
microspheres that can suspend or entrap a wide variety of 
substances, and can then be incorporated into a formulated 
product such as a gel, cream, liquid or powder. 
Microsponge drug delivery system can provide increased 
efficacy for topically active agents with enhanced safety, 
extended product stability and improved aesthetic 
properties in an efficient manner. To control the delivery 
rate of active agents to a predetermined site in the human 
body has been one of the biggest challenges faced by 
Pharmaceutical scientists. Several predictable and reliable 
systems have been developed for systemic delivery of drugs 
under the heading of transdermal delivery system (TDS) 
using the skin as portal of entry [3]. 
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Figure 1: Microsponge Technology 
 
The Microsponge Delivery System (Microsponge 
drug delivery system) is a patented polymeric system 
consisting of porous microspheres. They are tiny sponge 
like spherical particles that consist of a myriad of 
interconnecting voids within a noncollapsible structure with 
a large porous surface through which active ingredient are 
released in a controlled manner [4]. The size of the 
microsponges ranges from 5-300μm in diameter and a 
typical 25μm sphere can have up to 250000 pores and an 
internal pore structure equivalent to 10 feet in length, 
providing a total pore volume of about 1ml/g for extensive 
drug retention [5]. 
Potential features or characteristic of microsponge drug 
delivery systems
 
1) Microsponges exhibit good compatibility with various 
vehicles and ingredients. 
2) Microsponges have high entrapment efficiency. 
3) Microsponges are evaluated by free flowing properties 
[6]. 
4) Microsponges show acceptable stability over pH 
ranging from 1 to 11 and at high temperatures (up 
to130°C). 
5) The average pore size of microsponges is small (0.25 
μm) in a way to prevent the penetration of bacteria, thus 
they do not need sterilization or addition of 
preservatives. 
6) Microsponges are non-allergenic, non-irritating, non-
mutagenic and non-toxic. 
7) Microsponges can absorb oil up to 6 times their weight 
without drying [7]. 
Benefit of Microsponge drug delivery system
 
1) Improved formulation flexibility. 
2) Improved thermal, physical, and chemical stability. 
3) Flexibility to develop novel product forms. 
4) Microsponge systems are non-irritating, non-mutagenic, 
non-allergenic and non-toxic[8] 
5) Enhanced product performance. 
6) Extended release. 
7) Reduced irritation and hence improved patient 
Compliance. 
8) Effective product elegancy. 
9) Improved oil control as it can absorb oil up to 6 times its 
weight without drying[9] 
Characteristics of actives moieties that is entrapped into 
Microsponges
 
1) Active ingredients that are entrapped in microsponge 
can then be incorporated into many products such as 
creams, gels, powders, lotions and soaps. 
2) Certain considerations are taken into account while, 
formulating the vehicle in order to achieve desired 
product characteristics. 
3) It should be either fully miscible in monomer as well as 
capable of being made miscible by addition of small 
amount of a water immiscible solvent. 
4) It should be inert to monomers and should not increase 
the viscosity of the mixture during formulation. 
5) It should be water immiscible or nearly only slightly 
soluble [10]. 
6) It should not collapse spherical structure of the 
microsponges. 
7) It should be stable in contact with polymerization 
catalyst and also in conditions of polymerization. 
8) The solubility of actives in the vehicle must be limited. 
9) If not, the vehicles will deplete the microsponges 
before the application. 
10) Not more than 10 to 12% w/w microsponges must be 
incorporated into the vehicle in order to avoid cosmetic 
problems. 
11) Payload and polymer design of the microsponges for 
the active must be optimized for required release rate 
for given. period of time[11] 
 
2. Applications of Microsponge Systems 
2.1 Topical Delivery 
Topical agents are a mainstay in cosmetics and the 
treatment of dermatological disorders. However, they are 
associated with substantial skin irritancy, especially in 
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sensitive patients. The rapid release and subsequent 
accumulation of the active ingredients of the topical agents 
have been associated with this irritancy. Microsponge 
delivery technology provides controlled release of the 
active ingredients onto the skin. Several microsphere-based 
topical agents have been evaluated for their safety and 
efficacy for cosmetic purposes and in the treatment of 
dermatological disorders, and are currently marketed in the 
US. These include formulations of benzoyl peroxide, 
tretinoic acid, HQ plus retinol, and 5-FU. Formulations of 
topical agents utilizing the Microsponge drug delivery 
system technology have shown little or no irritancy in 
patients with acne, photo damaged skin, hyper 
pigmentation, or AK, without sacrificing the efficacy of the 
agents [12]. 
2.2 Oral Delivery 
In oral drug delivery the microsponge system 
increase the rate of solubilization of poorly water soluble 
drugs by entrapping them in the microsponge system’s 
pores. As these pores are very small the drug is in effect 
reduced to microscopic particles and the significant 
increase in the surface area thus greatly increase the rate of 
solubilization. A Microsponge system offers the potential 
for active ingredients to remain within a protected 
environment and provide controlled delivery of oral 
medication to the lower gastrointestinal (GI) tract, where it 
will be released upon exposure to specific enzymes in the 
colon. If this approach is successful then it should open up 
entirely new opportunities for Microsponge drug delivery 
system. It has been shown that microsponge system 
enhances the solubilization of drugs which are poorly 
soluble by entrapping these drugs in their pores [13]. 
2.3 Bone substitutes  
Bone-substitute compounds were obtained by 
mixing pre-polymerised powders of 
polymethylmethacrylate and liquid methylmethacrylate 
monomer with two aqueous dispersions of a-tricalcium 
phosphate (a-TCP) grains and calcium-deficient 
hydroxyapatite (CDHA) powders. The final composites 
appeared to be porous. Osteo-conductivity and Osteo-
conductivity of the final composites were tested In-vivo by 
implantation in rabbits. Formation of new trabecular bone 
was observed inside the pores where the inorganic powders 
had been placed. The material produced shows a good level 
of biocompatibility, good osteointegration rate and 
osteogenetic properties [14]. 
2.4 Cardiovascular engineering using microsponge 
technology  
Biodegradable materials with autologous cell 
seeding, requires a complicated and invasive procedure that 
carries the risk of infection. A biodegradable graft material 
containing collagen microsponge that would permit the 
regeneration of autologous vessel tissue has developed. The 
ability of this material to accelerate in-situ cellularization 
with autologous endothelial and smooth muscle cells was 
tested with and without pre-cellularization. Poly (lactic-co-
glycolic acid) as a biodegradable scaffold was compounded 
with collagen microsponge to form a vascular patch 
material. Histological results showed the formation of an 
endothelial cell monolayer, a parallel alignment of smooth 
muscle cells, and reconstructed vessel wall with elastin and 
collagen fibres. The cellular and extracellular components 
in the patch had increased to levels similar to those in 
native tissue at 6 months. This patch shows promise as a 
bioengineered material for promoting in situ cellularization 
and the regeneration of autologous tissue in cardiovascular 
surgery [15]. 
2.5 Microsponges for Biopharmaceuticals Delivery 
The microsponge delivery system is employed for 
both in the delivery of biopharmaceuticals as well as in 
tissue engineering. Dai 2010 et al developed 3D scaffolds 
hybrid structures that have advantages of natural type I 
collagen and synthetic PLGA knitted mesh. The collagen 
microsponges facilitated cell seeding and tissue formation 
and mechanically strong PLGA mesh served as a skeleton. 
The scaffolds were divided into three groups: a) Thin: 
collagen microsponge formed in interstices of PLGA mesh; 
b) Semi: collagen microsponge formed on one side of 
PLGA mesh; c) Sandwich: collagen sponge formed on both 
sides of PLGA mesh [16]. 
Afrasim M et al. (2016) successfully developed 
Polymeric microsponge based system of Fluconazole was 
developed successfully using quasi‑emulsion solvent 
diffusion method for continual topical delivery up to an 
extended period so as to reduce application frequency, 
hypersensitive reactions allied to the conventional marketed 
formulation, and to improve bioavailability and safety. 
Implemented method was found to be simple, reproducible 
and rapid; which led to the formation of highly porous, 
spherical microsponges with good flow. Varied 
drug‑polymer ratio reflected remarkable effect on drug 
content, encapsulation efficiency, particle size, and drug 
release. Among the all prepared gels integrating 
FLZ‑loaded microsponges, the F1 formulation was chosen 
for further study on the basis of its superiority in terms of 
physiochemical characterization, production yield, drug 
content, entrapment efficiency, morphology, surface 
topography, intact particles percent, and particle size. The 
In-vitro drug release study outcomes showed highest 
regression values for the zero order models, and also 
established proficiency of F1 formulation for extended drug 
release (85.38% at 8 h) with respect to conventional 
marketed one. The In-vitro antifungal evaluation and 
stability study too depicted promising results. Thus, 
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microsponge based delivery system developed and 
investigated in present research approach was seems to be 
promising with respect to eradication of face fungus, 
candidiasis and numerous other fungal infections, along 
with the practical application in pharmaceuticals and 
cosmeceuticals.[17] 
Barde P. (2015), had concluded that Microsponges 
containing Terbinafine HCl were prepared using Eudragit 
RSPO as a polymer by quassi-emulsion solvent diffusion 
method. The developed microsponges formulation were 
optimised and further evaluated. It was observed that the 
polymer Eudragit RSPO and stabilizing agent PVA 
concentration influenced the particle size and drug content 
of formed microsponges. The production yield, loading 
efficiency, surface morphology and particle size analysis 
was performed. The surface morphology including the pore 
structure of microsponges was evaluated using scanning 
electron microscopy. Microparticles were then incorporated 
in Carbopol 934 gel base and In-vitro permeation studies of 
formulations were performed in Franz diffusion cell. 
Surface morphology by scanning electron microscopy 
showed microporous nature of microsponges. Drug release 
was observed comparison with marketed formulation. The 
present study was to design, develop, and evaluate the 
microsponge incorporated gel for topical drug delivery of 
Terbinafine HCl for extended release. Mixture of Eudragit 
RSPO and drug in DCM act as internal phase. Solution of 
PVA in water used as external phase. Terbinafine HCl is 
easily inactivated by the gastric environment and produce 
gastric disturbances such as diarrhoea, nausea, abdominal 
pain and vomiting. The best formulation F4 was 
incorporated into gels and gels were evaluated for physical 
parameters and showed extended release up to 12h. 
Stability studies at room temperature showed that there was 
no noticeable change in the homogeneity, pH, spreadability, 
extrudability, viscosity, drug content and In-vitro release at 
the end of three months. Thus it was concluded that the 
optimized microsponges further can be incorporated into 
gel for topical application use as antifungal purpose. [18] 
Yadav P. et al (2014) had concluded that Skin has 
to bear various external traumas like wounds, burns, 
blisters, irritation etc. as well as topical diseases like 
psoriasis, vitilago, cancer and herpes. Various drug delivery 
systems like vesicles, microspheres, transdermal patches, 
nanoemulsions, microemulsions, microsponges etc. are 
available which are better than conventional drug delivery 
methods because these bypass systemic circulation as well 
as drug can be targeted directly to the required site. 
Microsponges are tiny sponge-like spherical particles with a 
large porous surface and provide controlled release. Herpes 
simplex is a viral disease occurring in two forms Herpes 
labialis and Herpes keratitis which occur on lips and 
epidermal layer of skin respectively. Conventional 
formulations used for treating herpes have various 
drawbacks like irritation, rashes, frequency of dosing and 
low bioavailability. Hence microsponge loaded topical 
preparations herbal gel and medicated lipstick of Acyclovir 
was prepared with a purpose to overcome these drawbacks. 
Microsponge loaded controlled release formulations of 
Acyclovir were prepared using quasi emulsion solvent 
diffusion method. The proposed formulations of Acyclovir 
loaded microsponges were characterized for particle size, 
production yield and entrapment efficiency. Porous 
structure of microsponges was confirmed by Scanning 
Electron Microscopy. After evaluation best optimized batch 
was incorporated in carbopol and aloe gel and lipstick base. 
Microsponge loaded herbal gel and lipstick were evaluated 
for various physical parameters. In- vitro release studies 
using diffusion cell revealed that the drug release followed 
Korsemeyer Peppas model. Microsponges containing 
Acyclovir were prepared by quasi emulsion solvent 
diffusion method using ethyl cellulose and PVA. By 
considering the solubility study of the drug and polymer 
and the rate of diffusion of the solvent used, the internal 
phase suitable for the preparation of microsponges to be 
ethanol and the external phase was found to be water. 
Mixture of Ethyl cellulose and drug in ethyl alcohol served 
as internal phase. Solution of PVA in water served as 
external phase. The concentration of the polymer required 
to produce microsponges with good physical and 
morphological characteristics was found to be 10-12% w/w 
of the drug. The minimum concentration of an emulsifier 
PVA required to produce microsponges was found to be 50 
mg per 200ml. The particle size range increases as increase 
in amount of polymer in the formulation. [19] 
Ravi R. (2013) had concluded that Acne is a 
common inflammatory skin disease that mainly affects the 
face, neck, chest and upper back. Treatment depends on 
severity. Erythromycin has bacteriostatic activity which 
inhibits the growth of bacteria. They mainly act by binding 
to the 50s subunits of bacteria, 70s r-RNA complex, and 
protein synthesis. Erythromycin is also used topically to 
treat acne. They are used to treat moderate to severe 
inflammatory acnes or acne that isn’t getting better with 
other treatments. Erythromycin works to treat acne by 
reducing the amount of acne causing bacteria called 
“propionibacteria” acnes on the skin; it also lessens 
inflammation and redness. Erythromycin is easily 
inactivated by the gastric environment and produce gastric 
disturbances such as diarrhoea, nausea, abdominal pain and 
vomiting. Erythromycin microsponges were prepared using 
quassi emulsion solvent diffusion method. Erythromycin 
microsponges were then incorporated into a Carbopol-940 
gel prepared by hydrogel technique for release studies. The 
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best formulation was found to be stable at room 
temperature for 3 months. Thus it was concluded that 
erythromycin can be formulated as microsponge gel that 
can release the drug up to 8hrs with reduced side effects. 
[20] 
Mohan K et al (2013) had concluded that Impetigo 
is a chronic, contagious bacterial skin infection caused by 
Staphylococcus aureus, Streptococcus pyogenes or both and 
usually treated with systemic antibiotics. Mupirocin is a 
medium potency, synthetic, topical antibacterial agent used 
in the treatment of impetigo. Percutaneous absorption is a 
risk associated with topically administered formulations. 
Controlled release of the drug to the skin could reduce the 
side effects while reducing percutaneous absorption. 
Therefore, the aim of the study was to produce mupirocinen 
trapped microsponges to control the release of the drug to 
the skin. Mupirocin microsponges were prepared using an 
emulsion solvent diffusion method. In order to optimize the 
microsponge formulation, factors affecting the physical 
properties of microsponges were determined. FT-IR and 
SEM was used to study the shape and morphology of 
microsponges. Mupirocin microsponges were then 
incorporated into a vanishing cream base for release 
studies. It was shown that the drug: polymer ratio, stirring 
rate, volume of external and internal phase influenced the 
particle size and drug release behavior of microsponges. 
The results showed that an increase in the ratio of the drug: 
polymer resulted in a reduction in the release rate of 
Mupirocin from microsponges. Kinetic analysis showed 
that the main mechanism of drug release was by Higuchi 
matrix- controlled diffusion. Quasi–emulsion solvent 
diffusion seems to be a promising method for the 
preparation of MUP microsponges as it is a rapid, easy, 
reproducible method and has an advantage of avoiding 
solvent toxicity. In this method there is formation of quasi-
emulsion droplets. The rapid diffusion of solvent into the 
aqueous medium might reduce the solubility of polymer in 
the droplets, since the polymer is insoluble in water. The 
instant mixing of the ethanol and water at the interface of 
the droplets induce precipitation of the polymer thus 
forming a shell enclosing the solvent and dissolved drug. 
Counter diffusion of solvent and water through the shell 
promotes further crystallization of the drug in the droplets 
of the polymer from the interior core. The finely dispersed 
droplets of the polymer solution of the drug were solidified 
in the aqueous phase via diffusion of solvent. [21] 
Saboji J et al (2011) had concluded that 
Microsponge containing Ketoconazole drug with six 
different proportions of Eudragit RS 100 as polymer were 
obtained successfully using quasi-emulsion solvent 
diffusion method. These formulations were studied for 
particle size and physical characterization. The physical 
characterization showed that microsponge formulation MS 
IV and MS VI showed a better loading efficiency and 
production yield. These two microsponge formulation were 
prepared as gel in 0.35 %w/w carbopol and studied for pH, 
viscosity, spreadability, drug content, In-vitro release, 
antimicrobial activity and In-vivo antifungal activity studied 
on guinea pig skin. The microsponge formulation gel, MKG 
1 showed viscosity 4390 cps, spreadability of 19.27 g cm/s 
and drug content of 85.2%. The antimicrobial studies 
showed zone of inhibition with 13.5 mm and 12.0 mm for 
microsponge formulation gel MKG 1 and MKG 2 
respectively when compared with pure drug, zone of 
inhibition 18.2 mm. These formulations also showed better 
antifungal activity on fungal induced guinea pig skin when 
compared with control group without application of drug. 
The microsponge ketoconazole gel formulations showed an 
appropriate drug release profile and also bring remarkable 
decrease on gel application for fungal treatment. [22] 
Sabyasachi M et al (2011), were prepared xanthan 
gum-facilitated ethyl cellulose microsponges by the double 
emulsification technique and further dispersed in a carbopol 
gel base for controlled delivery of diclofenac sodium to the 
skin. Scanning electron microscopy revealed the porous, 
spherical nature of the microsponges. Increase in the drug/ 
polymer ratio increased their yield, drug entrapment 
efficiency and mean particle diameter; when an equivalent 
amount of pure drug (not entrapped into microsponges) was 
dispersed into the gel base and the flux was compared, the 
microsponges. Whether the drug was dispersed either in un-
entrapped or entrapped form into the gel base, the drug 
permeation through rat skin followed Higuchi’s diffusion 
kinetic model. The microsponges prepared at the lowest 
drug/polymer ratio exhibited a comparatively slower drug 
permeation profile and were hence considered most suitable 
for controlled drug delivery application. FTIR spectroscopy 
and DSC analyses indicated the chemically stable, 
amorphous nature of the drug in these microsponges. The 
gel containing these optimized microsponges was 
comparable to that of a commercial gel formulation and did 
not show serious dermal reactions. Hence, the microsponge 
system obtained at the lowest drug/polymer ratio could be 
useful for controlled release of diclofenac sodium to the 
skin. [23] 
Netal A et al (2009) concluded that to develop and 
evaluate microsponge-based topical delivery system of 
mupirocin for sustained release and enhanced drug 
deposition in the skin. Microsponges containing mupirocin 
were prepared by an emulsion solvent diffusion method. 
The effect of formulation and process variables such as 
internal phase volume and stirring speed on the physical 
characteristics of microsponges were examined on 
optimized drug/polymer ratio by 32 factorial designs. The 
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optimized microsponges were incorporated into an emulgel 
base. In-vitro drug release, ex vivo drug deposition, and In-
vivo antibacterial activity of mupirocin-loaded formulations 
were studied. Developed microsponges were spherical and 
porous, and there was no interaction between drug and 
polymer molecules. Emulgels containing microsponges 
showed desired physical properties. Drug release through 
cellulose dialysis membrane showed diffusion-controlled 
release pattern and drug deposition studies using rat 
abdominal skin exhibited significant retention of active in 
skin from microsponge-based formulations by 24 h. The 
optimized formulations were stable and nonirritant to skin 
as demonstrated by Draize patch test. Microsponges-based 
emulgel formulations showed prolonged efficacy in mouse 
surgical wound model infected with S. aureus. Mupirocin 
was stable in topical emulgel formulations and showed 
enhanced retention in the skin indicating better potential of 
the delivery system for treatment of primary and secondary 
skin infections, such as impetigo, eczema, and atopic 
dermatitis. [24] 
Jain and Singh (2009), had concluded that 
paracetamol loaded eudragit based microsponges were 
prepared using quasi-emulsion solvent diffusion method. 
The compatibility of the drug with various formulation 
components was established. Process parameters were 
analysed in order to optimize the formulation. Shape and 
surface morphology of the microsponges were examined 
using scanning electron microscopy. The colon specific 
formulations were prepared by compression coating of 
microsponges with pectin: hydroxyl propylmethyl cellulose 
(HPMC) mixture followed by tableting. The In-vitro 
dissolution studies were done on all formulations and the 
results were evaluated kinetically and statically. The 
kinetics of release study showed that the release data 
followed Higuchi matrix and the main mechanism of drug 
release from microsponges was diffusion. In-vitro studies 
exhibited that compression coated colon specific tablet 
formulations started the release the drug at the 6th hour 
corresponding to the arrival time to proximal colon. [25] 
Mine O et al (2006) concluded that to design novel 
colon specific drug delivery system containing flurbiprofen 
(FLB) microsponges. Microsponges containing FLB and 
Eudragit RS100 were prepared by quasi-emulsion solvent 
diffusion method. Additionally, FLB was entrapped into a 
commercial microsponge® 5640 system using entrapment 
method. Afterwards, the effects of drug: polymer ratio, 
inner phase solvent amount, stirring time and speed and 
stirrer type on the physical characteristics of microsponges 
were investigated. The thermal behaviour, surface 
morphology, particle size and pore structure of 
microsponges were examined. The colon specific 
formulations were prepared by compression coating and 
also pore plugging of microsponges with pectin: 
hydroxypropylmethyl cellulose (HPMC) mixture followed 
by tableting. In-vitro dissolution studies were done on all 
formulations and the results were kinetically and 
statistically evaluated. The pore shapes of microsponges 
prepared by quasi-emulsion solvent diffusion method and 
entrapment method were found as spherical and cylindrical 
holes, respectively. Mechanically strong tablets prepared 
for colon specific drug delivery were obtained owing to the 
plastic deformation of sponge-like structure of 
microsponges. In-vitro studies exhibited that compression 
coated colon specific tablet formulations started to release 
the drug at the 8th hour corresponding to the proximal 
colon arrival time due to the addition of enzyme, following 
a modified release pattern while the drug release from the 
colon specific formulations prepared by pore plugging the 
microsponges showed an increase at the 8th hour which was 
the time point that the enzyme addition made. This study 
presents a new approach based on microsponges for colon 
specific drug delivery. [26] 
 
3. Conclusion 
As formulators consider new and creative ways to 
deliver actives, they can realize the full capabilities of these 
unique materials providing enhanced safety, improved 
stability, reduced side effects from actives, enhanced multi 
functionality and improved ingredient compatibility. 
Complemented by novel development approaches and 
creative formulation techniques, Microsponge delivery 
system can be a winning strategy for a new generation of 
Pharmaceutical and Cosmetic industry. Microsponges have 
a distinct advantage over the existing conventional topical 
dosage forms for the treatment of tropical diseases; it is a 
unique technology for the controlled release of topical 
agents also use for oral as well as biopharmaceutical drug 
delivery. This shows advantageous over other products by 
non-mutagenic, non-toxic, non-irritant. So microsponge 
drug delivery system has got a lot of potential and is a very 
emerging field which is needed to be explored in the future 
with most research study. 
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